CELZ
Creative Medical Technology Holdings Inc
$
3.032
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.070
Open
2.950
VWAP
2.92
Vol
91.02K
Mkt Cap
7.28M
Low
2.770
Amount
265.43K
EV/EBITDA(TTM)
--
Total Shares
1.35M
EV
1.90M
EV/OCF(TTM)
--
P/S(TTM)
1.04K
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2024Q4
FY2024Q3
0.00
-100%
--
--
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Creative Medical Technology Holdings, Inc. (CELZ) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.24%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-1.24%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Creative Medical Technology Holdings Inc (CELZ.O) is -1.82, compared to its 5-year average forward P/E of -1.23. For a more detailed relative valuation and DCF analysis to assess Creative Medical Technology Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.23
Current PE
-1.82
Overvalued PE
0.89
Undervalued PE
-3.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
595.74
Current PS
2.82
Overvalued PS
1874.06
Undervalued PS
-682.58
Financials
Annual
Quarterly
FY2025Q3
0.00
Total Revenue
FY2025Q3
YoY :
+14.72%
-1.27M
Operating Profit
FY2025Q3
YoY :
+18.82%
-1.24M
Net Income after Tax
FY2025Q3
YoY :
-36.00%
-0.48
EPS - Diluted
FY2025Q3
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q3
YoY :
+190.97%
-3.02K
Gross Profit Margin - %
FY2025Q3
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q3
YoY :
+200.95%
-136.91K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
8.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
8.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CELZ News & Events
Events Timeline
2025-10-30 (ET)
2025-10-30
09:19:59
Creative Medical Introduces Veterans Initiative for Biodefense Inc.
2025-10-29 (ET)
2025-10-29
09:08:34
Creative Medical Reveals Warrant Exercise Agreements Expected to Generate $4.2M in Proceeds
2025-10-27 (ET)
2025-10-27
08:26:31
Creative Medical Sends Letter to Shareholders
Sign Up For More Events
Sign Up For More Events
News
5.0
10-30NewsfilterCreative Medical Technology Holdings, Inc. Launches Innovative Regenerative BioDefense Program for U.S. Veterans Affected by Burn Pits
9.0
10-27NewsfilterCreative Medical Technology Holdings Sends Letter to Shareholders
9.0
10-07NewsfilterCreative Medical Technology Holdings Celebrates 2025 Nobel Prize Winners for Advances in Regulatory T Cell Research
Sign Up For More News
People Also Watch
FAQ
What is Creative Medical Technology Holdings Inc (CELZ) stock price today?
The current price of CELZ is 3.032 USD — it has increased 7.52 % in the last trading day.
What is Creative Medical Technology Holdings Inc (CELZ)'s business?
What is the price predicton of CELZ Stock?
What is Creative Medical Technology Holdings Inc (CELZ)'s revenue for the last quarter?
What is Creative Medical Technology Holdings Inc (CELZ)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Creative Medical Technology Holdings Inc (CELZ)'s fundamentals?
How many employees does Creative Medical Technology Holdings Inc (CELZ). have?